Biosimilars and Follow-On Biologics Market Report 2024-2034

Overall world revenue for Biosimilars and Follow-on Biologics Market, 2024 to 2034 in terms of value the market will surpass US$33,000 million in 2024, the work calculates. The publisher predicts strong revenue growth through to 2034. The work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

The Biosimilars and Follow-on Biologics Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increasing Demand of Drugs For Treating Chronic Conditions

The increasing demand for drugs stems from their remarkable efficacy in treating a wide array of chronic and complex diseases, ranging from cancer to autoimmune disorders and beyond. Chronic conditions such as diabetes, rheumatoid arthritis, and various forms of cancer are becoming increasingly prevalent, driving up the need for effective long-term treatments. This surge is propelled by various factors, including the aging population, the prevalence of lifestyle-related ailments, and advancements in medical science enabling earlier detection and prolonged treatment.

As our understanding of disease mechanisms deepens, biologics continue to be at the forefront of medical innovation, offering hope for patients with previously untreatable conditions. Additionally, heightened awareness and evolving healthcare policies advocating proactive management of chronic illnesses further contribute to the increasing demand for these drugs.

Favourable regulatory policies for approval of biosimilars

Regulatory agencies around the world have recognized the importance of establishing clear and transparent pathways for the approval of biosimilars, ensuring that these products meet stringent standards of quality, safety, and efficacy.

One of the key elements of favourable regulatory policies is the establishment of specific guidelines and frameworks tailored to the unique characteristics of biosimilars. Unlike small molecule drugs, which can be replicated with relative ease, biologics are large, complex molecules produced in living cells, making their development and characterization more challenging. Regulatory pathways allow biosimilar manufacturers to rely on existing clinical data for reference biologics, expediting the approval process while still requiring robust comparative analytical and clinical studies to demonstrate similarity and safety. By providing clear expectations and requirements, these guidelines enable manufacturers to navigate the regulatory process more efficiently and effectively, accelerating the development and approval of biosimilars.

Moreover, favourable regulatory policies include provisions to expedite the review and approval of biosimilar products, fostering competition and expanding patient access to affordable treatments. Regulatory agencies may employ mechanisms such as abbreviated pathways or priority review designations to streamline the approval process for biosimilars, particularly for products targeting diseases with significant unmet medical needs. These expedited pathways help bring biosimilar products to market more quickly, encouraging innovation and investment in the biosimilars space.

Key Questions Answered

How is the Biosimilars and Follow-on Biologics Market evolving?
What is driving and restraining the Biosimilars and Follow-on Biologics Market?
How will each Biosimilars and Follow-on Biologics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
How will the market shares for each Biosimilars and Follow-on Biologics submarket develop from 2024 to 2034?
What will be the main driver for the overall market from 2024 to 2034?
Will leading Biosimilars and Follow-on Biologics Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
Who are the leading players and what are their prospects over the forecast period?
What are the Biosimilars and Follow-on Biologics projects for these leading companies?
How will the industry evolve during the period between 2024 and 2034? What are the implications of Biosimilars and
Follow-on Biologics projects taking place now and over the next 10 years?
Is there a greater need for product commercialisation to further scale the Biosimilars and Follow-on Biologics Market?
Where is the Biosimilars and Follow-on Biologics Market heading and how can you ensure you are at the forefront of the market?
What are the best investment options for new product and service lines?
What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Biosimilars and Follow-on Biologics market today, and over the next 10 years:

This 391-page report provides 156 tables and 200 charts/graphs exclusively to you.
The report highlights key lucrative areas in the industry so you can them - NOW.
It contains in-depth analysis of global, regional and national sales and growth.
It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Biosimilars and Follow-on Biologics Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, the new study provides you with recent results, growth rates, and market shares.
You will find original analyses, with business outlooks and developments.
Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Biosimilars and Follow-on Biologics prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Product Type

Recombinant Non-Glycosylated Proteins
Human Growth Hormone
Granulocyte Colony-Stimulating Factor (Filgrastim)
Insulin
Interferon
Recombinant Glycosylated Proteins
Erythropoietin
Monoclonal Antibodies (Infliximab, Rituximab, Adalimumab, Trastuzumab, Bevacizumab, Etanercept)
Follitropin
Low Molecular Weight Heparin

Application

Hematology
Neutropenia
Anemia
Others
Oncology
Lung Cancer
Brain Cancer
Breast Cancer
Cervical Cancer
Colorectal Cancer
Leukemia
Others
Autoimmune Disease
Arthritis (Rheumatoid Arthritis, Psoriatic Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Others)
Inflammatory Bowel Disease (Ulcerative Colitis, Crohn’s Diseases, Others)
Psoriasis
Others
Growth Hormone Deficiency
Diabetes
Others

Technology

Recombinant DNA (rDNA) Technology
Monoclonal Antibodies (MAb) Technology

Manufacturer

Contract Research and Manufacturing Services
In-house

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for four regional and 27 leading national markets:

North America

U.S.
Canada

Europe

Germany
UK
France
Spain
Italy
Russia
Poland
Belgium
Rest of Europe

Asia Pacific

China
Japan
India
Australia
South Korea
Singapore
Taiwan
Rest of Asia Pacific

Latin America

Brazil
Mexico
Argentina
Colombia
Rest of Latin America

MEA

GCC
South Africa
Rest of MEA

The report also includes profiles and for some of the leading companies in the Biosimilars and Follow-on Biologics Market, 2024 to 2034, with a focus on this segment of these companies’ operations.

Leading companies profiled in the report

Amgen Inc.
Apotex (Apobiologix)
Biocad
Biocon Biologics Ltd.
Bio-Thera Solutions
Coherus Biosciences
Dr. Reddy’s Laboratories
Fresenius Kabi (Fresenius SE & Co. KGaA)
Intas Pharma
Pfizer
Reliance Life Sciences
Samsung Bioepis (Samsung Biologics)
Sandoz Group AG
Teva Pharmaceuticals Industries Ltd.

How will the Biosimilars and Follow-on Biologics Market, 2024 to 2034 report help you?

In summary, the 390+ page report provides you with the following knowledge:

Revenue forecasts to 2034 for Biosimilars and Follow-on Biologics Market, 2024 to 2034, with forecasts for product type, application, technology and manufacturer each forecast at a global and regional level - discover the industry’s prospects, finding the most lucrative places for investments and revenues.
Revenue forecasts to 2034 for five regional and 28 key national markets - See forecasts for the Biosimilars and Follow-on Biologics Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Argentina, Germany, France, UK, Spain, Italy, Russia, Poland, Belgium, China, India, Japan, Australia, South Korea, Singapore, Taiwan, GCC, and South Africa among other prominent economies.
Prospects for established firms and those seeking to enter the market - including company profiles for 14 of the major companies involved in the Biosimilars and Follow-on Biologics Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only this report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With this new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how this work could benefit your research, analyses, and decisions. This study is for everybody needing commercial analyses for the Biosimilars and Follow-on Biologics Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

1 Report Overview

1.1 Objectives of the Study
1.2 Introduction to Biosimilars and Follow-On Biologics Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About the Publisher

2 Executive Summary

3 Market Overview

3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Expiration of Patents for Original Biologics in the recent years
3.2.1.2 Increasing Incidence of Chronic Diseases
3.2.1.3 Established Clear Guidelines for the Approval of Biosimilars
3.2.2 Market Restraining Factors
3.2.2.1 High Development Costs of follow-on biologics
3.2.2.2 Lack of Interchangeability Between Biosimilars and Their Reference Biologics
3.2.2.3 Intellectual Property Issues and Other Legal Challenges
3.2.3 Market Opportunities
3.2.3.1 Development of Biosimilar Versions of Monoclonal Antibodies
3.2.3.2 Growing Demand for Affordable Biologics in Emerging Markets
3.2.3.3 Expanding the Portfolio of Biosimilars for Rare Diseases
3.3 COVID-19 Impact Analysis
3.4 Biosimilars Revenue by Region
3.4.1 Worldwide
3.4.2 United States
3.4.3 Japan
3.5 Biosimilars Latest Expected Approvals
3.5.1 United States
3.5.2 Europe
3.6 Latest Biosimilar Product Deals
3.7 List of Approved Biosimilars
3.8 List of Recently Launched Biosimilars
3.9 Porter’s Five Forces Analysis
3.9.1 Bargaining Power of Suppliers
3.9.2 Bargaining Power of Buyers
3.9.3 Competitive Rivalry
3.9.4 Threat of Substitutes
3.9.5 Threat of New Entrants
3.10 PEST Analysis

4 Biosimilars and Follow-On Biologics Market Analysis by Product Type

4.1 Key Findings
4.2 Product Type Segment: Market Attractiveness Index
4.3 Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Product Type
4.4 Recombinant Non-Glycosylated Proteins
4.4.1 Recombinant Non-Glycosylated Proteins Market by Product Type
4.4.2 Market Size by Region, 2024-2034 (US$ Million)
4.4.3 Market Share by Region, 2024 & 2034 (%)
4.4.4 Human Growth Hormone
4.4.4.1 Market Size by Region, 2024-2034 (US$ Million)
4.4.4.2 Market Share by Region, 2024 & 2034 (%)
4.4.5 Granulocyte Colony-Stimulating Factor (Filgrastim)
4.4.5.1 Market Size by Region, 2024-2034 (US$ Million)
4.4.5.2 Market Share by Region, 2024 & 2034 (%)
4.4.6 Insulin
4.4.6.1 Market Size by Region, 2024-2034 (US$ Million)
4.4.6.2 Market Share by Region, 2024 & 2034 (%)
4.4.7 Interferon
4.4.7.1 Market Size by Region, 2024-2034 (US$ Million)
4.4.7.2 Market Share by Region, 2024 & 2034 (%)
4.5 Recombinant Glycosylated Proteins
4.5.1 Recombinant Glycosylated Proteins Market by Product Type
4.5.2 Market Size by Region, 2024-2034 (US$ Million)
4.5.3 Market Share by Region, 2024 & 2034 (%)
4.5.4 Erythropoietin
4.5.4.1 Market Size by Region, 2024-2034 (US$ Million)
4.5.4.2 Market Share by Region, 2024 & 2034 (%)
4.5.5 Monoclonal Antibodies
4.5.5.1 Market Size by Monoclonal Antibodies, 2024-2034 (US$ Million)
4.5.5.2 Market Size by Region, 2024-2034 (US$ Million)
4.5.5.3 Market Share by Region, 2024 & 2034 (%)
4.5.6 Follitropin
4.5.6.1 Market Size by Region, 2024-2034 (US$ Million)
4.5.6.2 Market Share by Region, 2024 & 2034 (%)
4.5.7 Low Molecular Weight Heparin
4.5.7.1 Market Size by Region, 2024-2034 (US$ Million)
4.5.7.2 Market Share by Region, 2024 & 2034 (%)

5 Biosimilars and Follow-On Biologics Market Analysis by Application

5.1 Key Findings
5.2 Product Type Segment: Market Attractiveness Index
5.3 Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Application
5.4 Hematology
5.4.1 Hematology Market Forecast by Type
5.4.2 Market Size by Region, 2024-2034 (US$ Million)
5.4.3 Market Share by Region, 2024 & 2034 (%)
5.4.4 Neutropenia
5.4.4.1 Market Size by Region, 2024-2034 (US$ Million)
5.4.4.2 Market Share by Region, 2024 & 2034 (%)
5.4.5 Anemia
5.4.5.1 Market Size by Region, 2024-2034 (US$ Million)
5.4.5.2 Market Share by Region, 2024 & 2034 (%)
5.4.6 Others
5.4.6.1 Market Size by Region, 2024-2034 (US$ Million)
5.4.6.2 Market Share by Region, 2024 & 2034 (%)
5.5 Oncology
5.5.1 Oncology Market Forecast by Type
5.5.2 Market Size by Region, 2024-2034 (US$ Million)
5.5.3 Market Share by Region, 2024 & 2034 (%)
5.5.4 Lung Cancer
5.5.4.1 Market Size by Region, 2024-2034 (US$ Million)
5.5.4.2 Market Share by Region, 2024 & 2034 (%)
5.5.5 Brain Cancer
5.5.5.1 Market Size by Region, 2024-2034 (US$ Million)
5.5.5.2 Market Share by Region, 2024 & 2034 (%)
5.5.6 Breast Cancer
5.5.6.1 Market Size by Region, 2024-2034 (US$ Million)
5.5.6.2 Market Share by Region, 2024 & 2034 (%)
5.5.7 Cervical Cancer
5.5.7.1 Market Size by Region, 2024-2034 (US$ Million)
5.5.7.2 Market Share by Region, 2024 & 2034 (%)
5.5.8 Colorectal Cancer
5.5.8.1 Market Size by Region, 2024-2034 (US$ Million)
5.5.8.2 Market Share by Region, 2024 & 2034 (%)
5.5.9 Leukemia
5.5.9.1 Market Size by Region, 2024-2034 (US$ Million)
5.5.9.2 Market Share by Region, 2024 & 2034 (%)
5.5.10 Others
5.5.10.1 Market Size by Region, 2024-2034 (US$ Million)
5.5.10.2 Market Share by Region, 2024 & 2034 (%)
5.6 Autoimmune Disease
5.6.1 Autoimmune Disease Market Forecast by Type
5.6.2 Market Size by Region, 2024-2034 (US$ Million)
5.6.3 Market Share by Region, 2024 & 2034 (%)
5.6.4 Arthritis
5.6.4.1 Market Size by Type, 2024-2034 (US$ Million)
5.6.4.2 Market Size by Region, 2024-2034 (US$ Million)
5.6.4.3 Market Share by Region, 2024 & 2034 (%)
5.6.5 Inflammatory Bowel Disease
5.6.5.1 Market Size by Type, 2024-2034 (US$ Million)
5.6.5.2 Market Size by Region, 2024-2034 (US$ Million)
5.6.5.3 Market Share by Region, 2024 & 2034 (%)
5.6.6 Psoriasis
5.6.6.1 Market Size by Region, 2024-2034 (US$ Million)
5.6.6.2 Market Share by Region, 2024 & 2034 (%)
5.6.7 Others
5.6.7.1 Market Size by Region, 2024-2034 (US$ Million)
5.6.7.2 Market Share by Region, 2024 & 2034 (%)
5.7 Growth Hormone Deficiency
5.7.1 Market Size by Region, 2024-2034 (US$ Million)
5.7.2 Market Share by Region, 2024 & 2034 (%)
5.8 Diabetes
5.8.1 Market Size by Region, 2024-2034 (US$ Million)
5.8.2 Market Share by Region, 2024 & 2034 (%)
5.9 Others
5.9.1 Market Size by Region, 2024-2034 (US$ Million)
5.9.2 Market Share by Region, 2024 & 2034 (%)

6 Biosimilars and Follow-On Biologics Market Analysis by Technology

6.1 Key Findings
6.2 Technology Segment: Market Attractiveness Index
6.3 Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Technology
6.4 Recombinant DNA (rDNA) Technology
6.4.1 Market Size by Region, 2024-2034 (US$ Million)
6.4.2 Market Share by Region, 2024 & 2034 (%)
6.5 Monoclonal Antibodies (MAb) Technology
6.5.1 Market Size by Region, 2024-2034 (US$ Million)
6.5.2 Market Share by Region, 2024 & 2034 (%)

7 Biosimilars and Follow-On Biologics Market Analysis by Manufacturer

7.1 Key Findings
7.2 Product Type Segment: Market Attractiveness Index
7.3 Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Manufacturer
7.4 Contract Research and Manufacturing Services
7.4.1 Market Size by Region, 2024-2034 (US$ Million)
7.4.2 Market Share by Region, 2024 & 2034 (%)
7.5 In-house
7.5.1 Market Size by Region, 2024-2034 (US$ Million)
7.5.2 Market Share by Region, 2024 & 2034 (%)

8 Biosimilars and Follow-On Biologics Market Analysis by Region

8.1 Key Findings
8.2 Regional Market Size Estimation and Forecast

9 North America Biosimilars and Follow-On Biologics Market Analysis

9.1 Key Findings
9.2 North America Biosimilars and Follow-On Biologics Market Attractiveness Index
9.3 North America Biosimilars and Follow-On Biologics Market by Country, 2024, 2029 & 2034 (US$ Million)
9.4 North America Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Country
9.5 North America Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Product Type
9.6 North America Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Application
9.7 North America Biosimilars and Follow-On Biologics Market Size Estimation and Forecast Technology
9.8 North America Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Manufacturer
9.9 U.S. Biosimilars and Follow-On Biologics Market Analysis
9.10 Canada Biosimilars and Follow-On Biologics Market Analysis

10 Europe Biosimilars and Follow-On Biologics Market Analysis

10.1 Key Findings
10.2 Europe Biosimilars and Follow-On Biologics Market Attractiveness Index
10.3 Europe Biosimilars and follow-on biologics market by Country, 2024, 2029 & 2034 (US$ Million)
10.4 Europe Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Country
10.5 Europe Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Product Type
10.6 Europe Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Application
10.7 Europe Biosimilars and Follow-On Biologics Market Size Estimation and Forecast Technology
10.8 Europe Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Manufacturer
10.9 Germany Biosimilars and Follow-On Biologics Market Analysis
10.10 France Biosimilars and Follow-On Biologics Market Analysis
10.11 UK Biosimilars and Follow-On Biologics Market Analysis
10.12 Italy Biosimilars and Follow-On Biologics Market Analysis
10.13 Spain Biosimilars and Follow-On Biologics Market Analysis
10.14 Russia Biosimilars and Follow-On Biologics Market Analysis
10.15 Poland Biosimilars and Follow-On Biologics Market Analysis
10.16 Belgium Biosimilars and Follow-On Biologics Market Analysis
10.17 Rest of Europe Biosimilars and Follow-On Biologics Market Analysis

11 Asia Pacific Biosimilars and Follow-On Biologics Market Analysis

11.1 Key Findings
11.2 Asia Pacific Biosimilars and Follow-On Biologics Market Attractiveness Index
11.3 Asia Pacific Biosimilars and Follow-On Biologics Market by Country, 2024, 2029 & 2034 (US$ Million)
11.4 Asia Pacific Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Country
11.5 Asia Pacific Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Product Type
11.6 Asia Pacific Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Application
11.7 Asia Pacific Biosimilars and Follow-On Biologics Market Size Estimation and Forecast Technology
11.8 Asia Pacific Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Manufacturer
11.9 Japan Biosimilars and Follow-On Biologics Market Analysis
11.10 China Biosimilars and Follow-On Biologics Market Analysis
11.11 India Biosimilars and Follow-On Biologics Market Analysis
11.12 Australia Biosimilars and Follow-On Biologics Market Analysis
11.13 South Korea Biosimilars and Follow-On Biologics Market Analysis
11.14 Singapore Biosimilars and Follow-On Biologics Market Analysis
11.15 Taiwan Biosimilars and Follow-On Biologics Market Analysis
11.16 Rest of Asia Pacific Biosimilars and Follow-On Biologics Market Analysis

12 Latin America Biosimilars and Follow-On Biologics Market Analysis

12.1 Key Findings
12.2 Latin America Biosimilars and Follow-On Biologics Market Attractiveness Index
12.3 Latin America Biosimilars and Follow-On Biologics Market by Country, 2024, 2029 & 2034 (US$ Million)
12.4 Latin America Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Country
12.5 Latin America Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Product Type
12.6 Latin America Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Application
12.7 Latin America Biosimilars and Follow-On Biologics Market Size Estimation and Forecast Technology
12.8 Latin America Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Manufacturer
12.9 Brazil Biosimilars and Follow-On Biologics Market Analysis
12.10 Mexico Biosimilars and Follow-On Biologics Market Analysis
12.11 Argentina Biosimilars and Follow-On Biologics Market Analysis
12.12 Colombia Biosimilars and Follow-On Biologics Market Analysis
12.13 Rest of Latin America Biosimilars and Follow-On Biologics Market Analysis

13 MEA Biosimilars and Follow-On Biologics Market Analysis

13.1 Key Findings
13.2 MEA Biosimilars and Follow-On Biologics Market Attractiveness Index
13.3 MEA Biosimilars and Follow-On Biologics Market by Country, 2024, 2029 & 2034 (US$ Million)
13.4 MEA Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Country
13.5 MEA Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Product Type
13.6 MEA Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Application
13.7 MEA Biosimilars and Follow-On Biologics Market Size Estimation and Forecast Technology
13.8 MEA Biosimilars and Follow-On Biologics Market Size Estimation and Forecast by Manufacturer
13.9 GCC Biosimilars and Follow-On Biologics Market Analysis
13.10 South Africa Biosimilars and Follow-On Biologics Market Analysis
13.11 Rest of MEA Biosimilars and Follow-On Biologics Market Analysis

14 Company Profiles

14.1 Competitive Landscape, 2023
14.2 Strategic Outlook
14.3 Amgen Inc.
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Financial Analysis
14.3.3.1 Net Revenue, 2017-2023
14.3.3.2 R&D, 2017-2023
14.3.3.3 Regional Market Shares, 2023
14.3.4 Product Benchmarking
14.3.5 Strategic Outlook
14.4 Apotex (Apobiologix)
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Product Benchmarking
14.4.4 Strategic Outlook
14.5 Biocad
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Product Benchmarking
14.5.4 Strategic Outlook
14.6 Biocon Biologics Ltd.
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Financial Analysis
14.6.3.1 Net Revenue, 2017-2023
14.6.3.2 Regional Market Shares, 2023
14.6.4 Product Benchmarking
14.6.5 Strategic Outlook
14.7 Bio-Thera Solutions
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Product Benchmarking
14.7.4 Strategic Outlook
14.8 Coherus Biosciences
14.8.1 Company Snapshot
14.8.2 Company Overview
14.8.3 Financial Analysis
14.8.3.1 Net Revenue, 2019-2023
14.8.4 Product Benchmarking
14.8.5 Strategic Outlook
14.9 Dr. Reddy’s Laboratories
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Product Benchmarking
14.9.4 Strategic Outlook
14.10 Fresenius Kabi (Fresenius SE & Co. KGaA)
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Financial Analysis
14.10.3.1 Net Revenue, 2019-2023
14.10.3.2 Regional Market Shares, 2023
14.10.4 Product Benchmarking
14.10.5 Strategic Outlook
14.11 Intas Pharma
14.11.1 Company Snapshot
14.11.2 Company Overview
14.11.3 Product Benchmarking
14.11.4 Strategic Outlook
14.12 Pfizer
14.12.1 Company Snapshot
14.12.2 Company Overview
14.12.3 Financial Analysis
14.12.3.1 Net Revenue, 2017-2023
14.12.3.2 R&D, 2017-2023
14.12.3.3 Regional Market Shares, 2023
14.12.4 Product Benchmarking
14.12.5 Strategic Outlook
14.13 Reliance Life Sciences
14.13.1 Company Snapshot
14.13.2 Company Overview
14.13.3 Product Benchmarking
14.13.4 Strategic Outlook
14.14 Samsung Bioepis (Samsung Biologics)
14.14.1 Company Snapshot
14.14.2 Company Overview
14.14.3 Product Benchmarking
14.14.4 Strategic Outlook
14.15 Sandoz Group AG
14.15.1 Company Snapshot
14.15.2 Company Overview
14.15.3 Financial Analysis
14.15.3.1 Net Revenue, 2022-2023
14.15.3.2 Regional Market Shares, 2023
14.15.4 Product Benchmarking
14.15.5 Strategic Outlook
14.16 Teva Pharmaceuticals Industries Ltd.
14.16.1 Company Snapshot
14.16.2 Company Overview
14.16.3 Financial Analysis
14.16.3.1 Net Revenue, 2017-2023
14.16.3.2 R&D, 2017-2023
14.16.3.3 Regional Market Shares, 2023
14.16.4 Product Benchmarking
14.16.5 Strategic Outlook

15 Conclusion and Recommendations

15.1 Concluding Remarks
15.2 Recommendations for Market Players

List of Tables

Table 1 Biosimilars and Follow-On Biologics Market Snapshot, 2024 & 2034 (US$ Million, CAGR %)
Table 2 Cost comparison of a Biosimilars and their reference products
Table 3 Biosimilars and Follow-On Biologics Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): “V” Shaped Recovery
Table 4 Biosimilars and Follow-On Biologics Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): “U” Shaped Recovery
Table 5 Biosimilars and Follow-On Biologics Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): “W” Shaped Recovery
Table 6 Biosimilars and Follow-On Biologics Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%): “L” Shaped Recovery
Table 7 Worldwide Biosimilars Revenue 2023 (US$ Million)
Table 8 United States Biosimilars Revenue 2023 (US$ Million)
Table 9 Japan Biosimilars Revenue 2023 (US$ Million)
Table 10 United States Biosimilars Latest Expected Approvals
Table 11 Europe Biosimilars Latest Expected Approvals
Table 12 Europe Biosimilars Latest Expected Approvals
Table 13 List of Approved Biosimilars
Table 14 List of Recently Launched Biosimilars
Table 15 Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 16 Recombinant Non-Glycosylated Proteins Market by Product Type, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 17 Recombinant Non-Glycosylated Proteins Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 18 Human Growth Hormone Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 19 Granulocyte Colony-Stimulating Factor (Filgrastim) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 20 Insulin Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 21 Interferon Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 22 Recombinant Glycosylated Proteins Market by Product Type, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 23 Recombinant Glycosylated Proteins Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 24 Erythropoietin Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 25 Recombinant Glycosylated Proteins Segment Market Forecast by Monoclonal Antibodies, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 26 Monoclonal Antibodies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 27 Follitropin Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 28 Low Molecular Weight Heparin Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 29 Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 30 Hematology Market Forecast by Type, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 31 Hematology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 32 Neutropenia Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 33 Anemia Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 34 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 35 Oncology Market Forecast by Type, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 36 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 37 Lung Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 38 Brain Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 39 Breast Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 40 Cervical Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 41 Colorectal Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 42 Leukemia Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 43 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 44 Autoimmune Disease Market Forecast by Type, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 45 Autoimmune Disease Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 46 Autoimmune Disease Segment Market Forecast by Arthritis, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 47 Arthritis Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 48 Autoimmune Disease Segment Market Forecast by Inflammatory Bowel Disease, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 49 Inflammatory Bowel Disease Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 50 Psoriasis Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 51 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 52 Growth Hormone Deficiency Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 53 Diabetes Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 54 Others Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 55 Biosimilars and Follow-On Biologics Market Forecast by Technology, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 56 Recombinant DNA (rDNA) Technology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 57 Monoclonal Antibodies (MAb) Technology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 58 Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 59 Contract Research and Manufacturing Services Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 60 In-house Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 61 Biosimilars and Follow-On Biologics Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 62 North America Biosimilars and Follow-On Biologics Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 63 North America Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 64 North America Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 65 North America Biosimilars and Follow-On Biologics Market Forecast by Technology, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 66 Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 67 U.S. Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 68 Canada Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 69 Europe Biosimilars and Follow-On Biologics Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 70 Europe Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 71 Europe Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 72 Europe Biosimilars and Follow-On Biologics Market Forecast by Technology, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 73 Europe Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 74 Germany Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 75 France Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 76 UK Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 77 Italy Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 78 Spain Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 79 Russia Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 80 Poland Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 81 Belgium Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 82 Rest of Europe Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 83 Asia Pacific Biosimilars and Follow-On Biologics Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 84 Asia Pacific Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 85 Asia Pacific Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 86 Asia Pacific Biosimilars and Follow-On Biologics Market Forecast by Technology, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 87 Asia Pacific Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 88 Japan Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 89 China Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 90 India Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 91 Australia Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 92 South Korea Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 93 Singapore Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 94 Taiwan Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 95 Rest of Asia Pacific Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 96 Latin America Biosimilars and Follow-On Biologics Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 97 Latin America Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 98 Latin America Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 99 Latin America Biosimilars and Follow-On Biologics Market Forecast by Technology, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 100 Latin America Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 101 Brazil Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 102 Mexico Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 103 Argentina Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 104 Colombia Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 105 Rest of Latin America Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 106 MEA Biosimilars and Follow-On Biologics Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 107 MEA Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 108 MEA Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 109 MEA Biosimilars and Follow-On Biologics Market Forecast by Technology, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 110 MEA Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 111 GCC Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 112 South Africa Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 113 Rest of MEA Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 114 Strategic Outlook
Table 115 Amgen Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 116 Amgen Inc.: Product Benchmarking
Table 117 Amgen Inc.: Strategic Outlook
Table 118 Apotex (Apobiologix): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 119 Apotex (Apobiologix): Product Benchmarking
Table 120 Apotex (Apobiologix): Strategic Outlook
Table 121 Biocad: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 122 Biocad: Product Benchmarking
Table 123 Biocad: Strategic Outlook
Table 124 Biocon Biologics Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 125 Biocon Biologics Ltd.: Product Benchmarking
Table 126 Biocon Biologics Ltd.: Strategic Outlook
Table 127 Bio-Thera Solutions: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 128 Bio-Thera Solutions: Product Benchmarking
Table 129 Bio-Thera Solutions: Strategic Outlook
Table 130 Coherus Biosciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 131 Coherus Biosciences: Product Benchmarking
Table 132 Coherus Biosciences: Strategic Outlook
Table 133 Dr. Reddy’s Laboratories: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 134 Dr. Reddy’s Laboratories: Product Benchmarking
Table 135 Dr. Reddy’s Laboratories: Strategic Outlook
Table 136 Fresenius Kabi (Fresenius SE & Co. KGaA): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 137 Fresenius Kabi (Fresenius SE & Co. KGaA): Product Benchmarking
Table 138 Fresenius Kabi (Fresenius SE & Co. KGaA): Strategic Outlook
Table 139 Intas Pharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 140 Intas Pharma: Product Benchmarking
Table 141 Intas Pharma: Strategic Outlook
Table 142 Pfizer: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 143 Pfizer: Product Benchmarking
Table 144 Pfizer: Strategic Outlook
Table 145 Reliance Life Sciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 146 Reliance Life Sciences: Product Benchmarking
Table 147 Reliance Life Sciences: Strategic Outlook
Table 148 Samsung Bioepis (Samsung Biologics): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 149 Samsung Bioepis (Samsung Biologics): Product Benchmarking
Table 150 Samsung Bioepis (Samsung Biologics): Strategic Outlook
Table 151 Sandoz Group AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 152 Sandoz Group AG: Product Benchmarking
Table 153 Sandoz Group AG: Strategic Outlook
Table 154 Teva Pharmaceuticals Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 155 Teva Pharmaceuticals Industries Ltd.: Product Benchmarking
Table 156 Teva Pharmaceuticals Industries Ltd.: Strategic Outlook

List of Figures

Figure 1 Biosimilars and Follow-On Biologics Market Segmentation
Figure 2 Biosimilars and Follow-On Biologics Market by Product Type: Market Attractiveness Index
Figure 3 Biosimilars and Follow-On Biologics Market Application: Market Attractiveness Index
Figure 4 Biosimilars and Follow-On Biologics Market by Technology: Market Attractiveness Index
Figure 5 Biosimilars and Follow-On Biologics Market by Manufacturer: Market Attractiveness Index
Figure 6 Biosimilars and Follow-On Biologics Market Attractiveness Index by Region
Figure 7 Biosimilars and Follow-On Biologics Market: Market Dynamics
Figure 8 Biosimilars and Follow-On Biologics Market by Region, 2024-2034 (US$ Million, AGR %): “V” Shaped Recovery
Figure 9 Biosimilars and Follow-On Biologics Market by Region, 2024-2034 (US$ Million, AGR %): “U” Shaped Recovery
Figure 10 Biosimilars and Follow-On Biologics Market by Region, 2024-2034 (US$ Million, AGR %): “W” Shaped Recovery
Figure 11 Biosimilars and Follow-On Biologics Market by Region, 2024-2034 (US$ Million, AGR %): “L” Shaped Recovery
Figure 12 Biosimilars and Follow-On Biologics Market: Porter’s Five Forces Analysis
Figure 13 Biosimilars and Follow-On Biologics Market: PEST Analysis
Figure 14 Biosimilars and Follow-On Biologics Market by Product type: Market Attractiveness Index
Figure 15 Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR %)
Figure 16 Biosimilars and Follow-On Biologics Market Share Forecast by Product type, 2024, 2029, 2034 (%)
Figure 17 Recombinant Non-Glycosylated Proteins Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 18 Recombinant Non-Glycosylated Proteins Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 19 Human Growth Hormone Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 20 Human Growth Hormone Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 21 Granulocyte Colony-Stimulating Factor (Filgrastim) Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 22 Granulocyte Colony-Stimulating Factor (Filgrastim) Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 23 Insulin Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 24 Insulin Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 25 Interferon Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 26 Interferon Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 27 Recombinant Glycosylated Proteins Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 28 Recombinant Glycosylated Proteins Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 29 Erythropoietin Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 30 Erythropoietin Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 31 Monoclonal Antibodies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 32 Monoclonal Antibodies Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 33 Follitropin Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 34 Follitropin Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 35 Low Molecular Weight Heparin Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 36 Low Molecular Weight Heparin Market Share Forecast by Region, 2024 & 2034 (%)
Figure 37 Biosimilars and Follow-On Biologics Market by Application: Market Attractiveness Index
Figure 38 Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR %)
Figure 39 Biosimilars and Follow-On Biologics Market Share Forecast by Application, 2024, 2029, 2034 (%)
Figure 40 Hematology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 41 Hematology Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 42 Neutropenia Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 43 Neutropenia Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 44 Anemia Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 45 Anemia Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 46 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 47 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 48 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 49 Oncology Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 50 Lung Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 51 Lung Cancer Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 52 Brain Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 53 Brain Cancer Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 54 Breast Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 55 Breast Cancer Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 56 Cervical Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 57 Cervical Cancer Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 58 Colorectal Cancer Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 59 Colorectal Cancer Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 60 Leukemia Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 61 Leukemia Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 62 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 63 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 64 Autoimmune Disease Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 65 Autoimmune Disease Market Share Forecast by Region, 2024 & 2034 (%)
Figure 66 Arthritis Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 67 Arthritis Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 68 Inflammatory Bowel Disease Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 69 Inflammatory Bowel Disease Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 70 Psoriasis Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 71 Psoriasis Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 72 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 73 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 74 Growth Hormone Deficiency Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 75 Growth Hormone Deficiency Market Share Forecast by Region, 2024 & 2034 (%)
Figure 76 Diabetes Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 77 Diabetes Market Share Forecast by Region, 2024 & 2034 (%)
Figure 78 Others Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 79 Others Market Share Forecast by Region, 2024 & 2034 (%)
Figure 80 Biosimilars and Follow-On Biologics Market by Technology: Market Attractiveness Index
Figure 81 Biosimilars and Follow-On Biologics Market Forecast by Technology, 2024-2034 (US$ Million, AGR %)
Figure 82 Biosimilars and Follow-On Biologics Market Share Forecast by Technology, 2024, 2029, 2034 (%)
Figure 83 Recombinant DNA (rDNA) Technology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 84 Recombinant DNA (rDNA) Technology Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 85 Monoclonal Antibodies (MAb) Technology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 86 Monoclonal Antibodies (MAb) Technology Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 87 Biosimilars and Follow-On Biologics Market by Manufacturer: Market Attractiveness Index
Figure 88 Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR %)
Figure 89 Biosimilars and Follow-On Biologics Market Share Forecast by Manufacturer, 2024, 2029, 2034 (%)
Figure 90 Contract Research and Manufacturing Services Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 91 Contract Research and Manufacturing Services Market Share Forecast by Region, 2024 & 2034 (%)
Figure 92 In-house Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 93 In-house Market Share Forecast by Region, 2024 & 2034 (%)
Figure 94 Biosimilars and Follow-On Biologics Market Forecast by Region 2024 and 2034 (Revenue, CAGR %)
Figure 95 Biosimilars and Follow-On Biologics Market Share Forecast by Region 2024, 2029, 2034 (%)
Figure 96 Biosimilars and Follow-On Biologics Market by Region, 2024-2034 (US$ Million, AGR %)
Figure 97 North America Biosimilars and Follow-On Biologics Market Attractiveness Index
Figure 98 North America Biosimilars and Follow-On Biologics Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 99 North America Biosimilars and Follow-On Biologics Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 100 North America Biosimilars and Follow-On Biologics Market Share Forecast by Country, 2024 & 2034 (%)
Figure 101 North America Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR %)
Figure 102 North America Biosimilars and Follow-On Biologics Market Share Forecast by Product Type, 2024 & 2034 (%)
Figure 103 North America Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR %)
Figure 104 North America Biosimilars and Follow-On Biologics Market Share Forecast by Application, 2024 & 2034 (%)
Figure 105 North America Biosimilars and Follow-On Biologics Market Forecast Technology, 2024-2034 (US$ Million, AGR %)
Figure 106 North America Biosimilars and Follow-On Biologics Market Share Forecast Technology, 2024 & 2034 (%)
Figure 107 North America Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR %)
Figure 108 North America Biosimilars and Follow-On Biologics Market Share Forecast by Manufacturer, 2024 & 2034 (%)
Figure 109 U.S. Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 110 Canada Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 111 Europe Biosimilars and Follow-On Biologics Market Attractiveness Index
Figure 112 Europe Biosimilars and Follow-On Biologics Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 113 Europe Biosimilars and Follow-On Biologics Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 114 Europe Biosimilars and Follow-On Biologics Market Share Forecast by Country, 2024 & 2034 (%)
Figure 115 Europe Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR %)
Figure 116 Europe Biosimilars and Follow-On Biologics Market Share Forecast by Product Type, 2024 & 2034 (%)
Figure 117 Europe Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR %)
Figure 118 Europe Biosimilars and Follow-On Biologics Market Share Forecast by Application, 2024 & 2034 (%)
Figure 119 Europe Biosimilars and Follow-On Biologics Market Forecast Technology, 2024-2034 (US$ Million, AGR %)
Figure 120 Europe Biosimilars and Follow-On Biologics Market Share Forecast Technology, 2024 & 2034 (%)
Figure 121 Europe Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR %)
Figure 122 Europe Biosimilars and Follow-On Biologics Market Share Forecast by Manufacturer, 2024 & 2034 (%)
Figure 123 Germany Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 124 France Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 125 UK Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 126 Italy Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 127 Spain Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 128 Russia Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 129 Poland Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 130 Belgium Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 131 Rest of Europe Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 132 Asia Pacific Biosimilars and Follow-On Biologics Market Attractiveness Index
Figure 133 Asia Pacific Biosimilars and Follow-On Biologics Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 134 Asia Pacific Biosimilars and Follow-On Biologics Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 135 Asia Pacific Biosimilars and Follow-On Biologics Market Share Forecast by Country, 2024 & 2034 (%)
Figure 136 Asia Pacific Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR %)
Figure 137 Asia Pacific Biosimilars and Follow-On Biologics Market Share Forecast by Product Type, 2024 & 2034 (%)
Figure 138 Asia Pacific Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR %)
Figure 139 Asia Pacific Biosimilars and Follow-On Biologics Market Share Forecast by Application, 2024 & 2034 (%)
Figure 140 Asia Pacific Biosimilars and Follow-On Biologics Market Forecast Technology, 2024-2034 (US$ Million, AGR %)
Figure 141 Asia Pacific Biosimilars and Follow-On Biologics Market Share Forecast Technology, 2024 & 2034 (%)
Figure 142 Asia Pacific Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR %)
Figure 143 Asia Pacific Biosimilars and Follow-On Biologics Market Share Forecast by Manufacturer, 2024 & 2034 (%)
Figure 144 Japan Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 145 China Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 146 India Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 147 Australia Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 148 South Korea Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 149 Singapore Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 150 Taiwan Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 151 Rest of Asia Pacific Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 152 Latin America Biosimilars and Follow-On Biologics Market Attractiveness Index
Figure 153 Latin America Biosimilars and Follow-On Biologics Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 154 Latin America Biosimilars and Follow-On Biologics Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 155 Latin America Biosimilars and Follow-On Biologics Market Share Forecast by Country, 2024 & 2034 (%)
Figure 156 Latin America Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR %)
Figure 157 Latin America Biosimilars and Follow-On Biologics Market Share Forecast by Product Type, 2024 & 2034 (%)
Figure 158 Latin America Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR %)
Figure 159 Latin America Biosimilars and Follow-On Biologics Market Share Forecast by Application, 2024 & 2034 (%)
Figure 160 Latin America Biosimilars and Follow-On Biologics Market Forecast Technology, 2024-2034 (US$ Million, AGR %)
Figure 161 Latin America Biosimilars and Follow-On Biologics Market Share Forecast Technology, 2024 & 2034 (%)
Figure 162 Latin America Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR %)
Figure 163 Latin America Biosimilars and Follow-On Biologics Market Share Forecast by Manufacturer, 2024 & 2034 (%)
Figure 164 Brazil Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 165 Mexico Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 166 Argentina Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 167 Colombia Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 168 Rest of Latin America Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 169 MEA Biosimilars and Follow-On Biologics Market Attractiveness Index
Figure 170 MEA Biosimilars and Follow-On Biologics Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 171 MEA Biosimilars and Follow-On Biologics Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 172 MEA Biosimilars and Follow-On Biologics Market Share Forecast by Country, 2024 & 2034 (%)
Figure 173 MEA Biosimilars and Follow-On Biologics Market Forecast by Product Type, 2024-2034 (US$ Million, AGR %)
Figure 174 MEA Biosimilars and Follow-On Biologics Market Share Forecast by Product Type, 2024 & 2034 (%)
Figure 175 MEA Biosimilars and Follow-On Biologics Market Forecast by Application, 2024-2034 (US$ Million, AGR %)
Figure 176 MEA Biosimilars and Follow-On Biologics Market Share Forecast by Application, 2024 & 2034 (%)
Figure 177 MEA Biosimilars and Follow-On Biologics Market Forecast Technology, 2024-2034 (US$ Million, AGR %)
Figure 178 MEA Biosimilars and Follow-On Biologics Market Share Forecast Technology, 2024 & 2034 (%)
Figure 179 MEA Biosimilars and Follow-On Biologics Market Forecast by Manufacturer, 2024-2034 (US$ Million, AGR %)
Figure 180 MEA Biosimilars and Follow-On Biologics Market Share Forecast by Manufacturer, 2024 & 2034 (%)
Figure 181 GCC Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 182 South Africa Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 183 Rest of MEA Biosimilars and Follow-On Biologics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 184 Biosimilars and Follow-On Biologics Market: Company Share
Figure 185 Amgen Inc.: Net Revenue, 2017-2023 (US$ Million, AGR%)
Figure 186 Amgen Inc.: R&D, 2017-2023 (US$ Million, AGR%)
Figure 187 Amgen Inc.: Regional Market Shares, 2023
Figure 188 Biocon Biologics Ltd.: Net Revenue, 2017-2023 (US$ Million, AGR%)
Figure 189 Biocon Biologics Ltd.: Regional Market Shares, 2023
Figure 190 Coherus Biosciences: Net Revenue, 2019-2023 (US$ Million, AGR%)
Figure 191 Fresenius Kabi (Fresenius SE & Co. KGaA): Net Revenue, 2019-2023 (US$ Million, AGR%)
Figure 192 Fresenius Kabi (Fresenius SE & Co. KGaA): Regional Market Shares, 2023
Figure 193 Pfizer: Net Revenue, 2017-2023 (US$ Million, AGR%)
Figure 194 Pfizer R&D, 2017-2023 (US$ Million, AGR%)
Figure 195 Pfizer Regional Market Shares, 2023
Figure 196 Sandoz Group AG: Net Revenue, 2022-2023 (US$ Million, AGR%)
Figure 197 Sandoz Group AG: Regional Market Shares, 2023
Figure 198 Teva Pharmaceuticals Industries Ltd: Net Revenue, 2017-2023 (US$ Million, AGR%)
Figure 199 Teva Pharmaceuticals Industries Ltd: R&D, 2017-2023 (US$ Million, AGR%)
Figure 200 Teva Pharmaceuticals Industries Ltd: Regional Market Shares, 2023

Companies Mentioned

Amgen Inc.
Apotex (Apobiologix)
Biocad
Biocon Biologics Ltd.
Bio-Thera Solutions
Coherus Biosciences
Dr. Reddy’s Laboratories
Fresenius Kabi (Fresenius SE & Co. KGaA)
Intas Pharma
Pfizer
Reliance Life Sciences
Samsung Bioepis (Samsung Biologics)
Sandoz Group AG
Teva Pharmaceuticals Industries Ltd.
Allergan
Allogene Therapeutics
Amman Pharmaceuticals
Arbor Biotechnologies
Aspen Pharmacare
AstraZeneca Pharma
Aurobindo Pharma
Axantia Holding
Biogen
Celltrion Healthcare
Cipla
Glenmark Pharmaceuticals Ltd.
Johnson & Johnson
JSR Life Sciences
Laboratorios Legrand S.A
LG Chem
Lupin Limited
Mabwell
mAbxience
Macter International Ltd
Polpharma Biologics
Prestige Biopharma Limited
ProQR Therapeutics N.V.
WuXi Biologics
Central Drugs Standard Control Organisation (CDSCO)
European Society of Human Reproduction and Embryology (ESHRE)
European Society for Medical Oncology (ESMO) Congress
European Medicines Agency (EMA)
Food and Drug Administration (FDA)
World Health Organization (WHO)
National Medical Products Administration (NMPA)
Therapeutic Goods Administration (TGA)

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5292EUR$5,741USD£4,350GBP
1 - 5 USER LICENSE PDF	The product is a PDF.	This is a 1-5 user license, allowing up to five users have access to the product.	€6266EUR$6,797USD£5,150GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€7361EUR$7,984USD£6,050GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€9301EUR$10,089USD£7,645GBP